Evidence map›Paper›PMID 34661762›Full record

ArticleJournal, genetic engineering & biotechnology2021

NAFLD mark: an accurate model based on microRNA-34 for diagnosis of non-alcoholic fatty liver disease patients.

Amal A Mohamed, Ahmed El-Demery, Eman Al-Hussain, Shroouk Mousa, Ahmed Abdel Halim, Sahar M Mostafa, Reda S Abdelghany, Seham M Mahmoud, Mohammad A Elkady, Khaled Raafat and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal, genetic engineering & biotechnology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Review
  5. Review
  6. Article
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Amal A MohamedBiochemistry Department, National Hepatology and Tropical Medicine Research Institute, Cairo, Egypt.
Ahmed El-DemeryBiochemistry Department, Faculty of Medicine, October 6 University, 6th of October City, Egypt.
Eman Al-HussainClinical and Chemical Pathology, Faculty of Medicine, Cairo university, Giza, Egypt.
Shroouk MousaInternal Medicine Department, Faculty of Medicine, Cairo University, Cairo, Egypt.
Ahmed Abdel HalimTropical Department, National Hepatology and Tropical Medicine Research Institute, Cairo, Egypt.
Sahar M MostafaTropical Department, National Hepatology and Tropical Medicine Research Institute, Cairo, Egypt.
Reda S AbdelghanyTropical Medicine Department, Ahmed Maher Teaching Hospital, Cairo, Egypt.
Seham M MahmoudTropical Department, El-Sahel Teaching Hospital, Cairo, Egypt.
Mohammad A ElkadyTheodor Bilharz Research Institute Gastroenterology and Hepatology department, Cairo, Egypt.
Khaled RaafatGastroenterology and Hepatology Department, Faculty of Medicine, Ain Shams University, Cairo, Egypt.
Alshymaa A HassnineDepartment of Gastroenterology and Tropical Medicine, Faculty of Medicine, Minia University, Minia, Egypt.
Mohamed M OmranChemistry Department, Faculty of Science, Helwan University, Ain Helwan, Cairo, 11795, Egypt. drmmomran@science.helwan.edu.eg.ORCID http://orcid.org/0000-0001-8557-3104

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundIt remains essential for non-alcoholic fatty liver (NAFLD) patients, to develop a sensitive and specific diagnostic model. Data regarding the use of micro (mi)RNA-34 for NAFLD diagnosis are few. Routine clinical assessment, laboratory tests were done for Egyptian individuals (n = 314) were included (100 healthy individuals and 214 NAFLD patients). Quantification of miRNA-34 was done using real-time PCR. Extremely significant variables were entered into stepwise logistic regression. The diagnostic power of variables was estimated by the area under the ROC (AUC).

resultsMiRNA-34 levels were higher in NAFLD patients than healthy individuals with a significant difference (P< 0.0001). The multivariate analysis was used to evaluate the NAFLD-associated variables (CRP, cholesterol, body mass index (BMI), ALT had p< 0.0001 while mRNA-34 had (p=0.0004). The AUCs (CI) of candidate NAFLD markers were in the order of miRNA-34 0.72 (0.66-0.77) < ALT 0.73 (0.67-0.79) < BMI 0.81 (0.76-0.86) < cholesterol < 0.85 (0.79-0.90) < CRP 0.88 (0.84-0.92). We developed a novel index for discriminating patients with NAFLD named NAFLD Mark. AUC was jumped to 0.98 (0.93-0.99) when five markers were combined. The AUC of NAFLD mark for NAFLD detection was higher than the AUCs of seven common NAFLD indexes (0.44-0.86).

conclusionsThe NAFLD mark is a non-invasive and highly sensitive and specific model for NAFLD diagnosis.

Indexed as

Alanine aminotransferaseBody mass indexCholesterolC-reactive proteinMicroRNA-34Non-alcoholic fatty liver disease

Identifiers

PMID34661762
PMCPMC8523615

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.